0001193125-14-102686.txt : 20140317 0001193125-14-102686.hdr.sgml : 20140317 20140317172217 ACCESSION NUMBER: 0001193125-14-102686 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20140317 DATE AS OF CHANGE: 20140317 EFFECTIVENESS DATE: 20140317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-194634 FILM NUMBER: 14698507 BUSINESS ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 S-8 1 d693441ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on March 17, 2014

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ACELRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

   
  351 Galveston Drive  
  Redwood City, CA 94063  
Delaware   (650) 216-3500   41-2193603

(State or other jurisdiction of

incorporation or organization)

  

(Address of principal executive offices,

including zip code)

  

(I.R.S. Employer

Identification No.)

 

  2011 Equity Incentive Plan  
  (Full titles of the plans)  

 

 

Richard A. King

President and Chief Executive Officer

AcelRx Pharmaceuticals, Inc.

351 Galveston Drive

Redwood City, CA 94063 (650) 216-3500

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Mark B. Weeks

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

Facsimile: (650) 849-7400

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities

to be Registered

  

Amount to be

Registered(1)

  

Proposed Maximum

Offering

Price Per Share(2)

  

Proposed Maximum

Aggregate

Offering Price(2)

  

Amount of

Registration Fee

Common Stock, par value $0.001 per share

   1,722,023 shares   $11.62   $20,009,907.26   $2,577.28

 

 

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s Common Stock.
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock as reported on the NASDAQ Global Market on March 11, 2014.

 

 

 

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,722,023 shares of the common stock of AcelRx Pharmaceuticals, Inc. (the “Registrant”) to be issued pursuant to the Registrant’s 2011 Equity Incentive Plan.

INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENT ON FORM S-8

The contents of the Registration Statements on Form S-8 (File Nos. 333-172409, 333-180334 and 333-187206) are incorporated by reference herein.

EXHIBITS

 

Exhibit

Number

   

Description

  3.1    Amended and Restated Certificate of Incorporation of the Registrant.(1)
  3.2    Amended and Restated Bylaws of the Registrant.(2)
  4.1    Reference is made to Exhibits 3.1 and 3.2.
  4.2    Specimen Common Stock Certificate of the Registrant.(3)
  4.3    Second Amended and Restated Investor’s Rights Agreement, among the Registrant and certain of its security holders, dated as of November 23, 2009.(4)
  4.4    Warrant to Purchase Stock of the Registrant, issued to Wells Fargo Bank, N.A., dated March 15, 2007.(5)
  4.5    Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P., dated as of December 16, 2013.(6)
  4.6    Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, dated as of December 16, 2013.(7)
  4.7    Form of Warrant issued to certain purchasers pursuant to the Securities Purchase Agreement dated May 29, 2012, between the Registrant and the purchasers identified therein.(8)
  5.1    Opinion of Cooley LLP.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Cooley LLP (included in Exhibit 5.1).
24.1    Power of Attorney. Reference is made to the signature page of this Form S-8.
99.1    2011 Equity Incentive Plan.(9)
99.2    Forms of Stock Option Grant Notice, Stock Option Exercise Notice and Stock Option Agreement under 2011 Equity Incentive Plan.(10)
99.3    Form of Restricted Stock Unit Award Agreement under 2011 Equity Incentive Plan.(11)

 

(1) Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35068), as filed with the Commission on February 18, 2011.
(2) Incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on January 7, 2011, as amended.
(3) Incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on January 31, 2011, as amended.
(4) Incorporated herein by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on November 12, 2010, as amended.
(5) Incorporated herein by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on November 12, 2010, as amended.
(6) Incorporated herein by reference to Exhibit 4.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 17, 2014.
(7) Incorporated herein by reference to Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 17, 2014.
(8) Incorporated herein by reference to Exhibit 4.8 to the Registrant’s Current Report on Form 8-K (File No. 001-35068), as filed with the Commission on May 30, 2012.
(9) Incorporated herein by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-172409), as filed with the Commission on February 24, 2011.
(10) Incorporated herein by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 30, 2011.
(11) Incorporated herein by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 30, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 17th day of March, 2014.

 

ACELRX PHARMACEUTICALS, INC.

By:

  

/s/ RICHARD A. KING

  Richard A. King
  President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints RICHARD A. KING and JAMES H. WELCH, jointly and severally, as his true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

     

Title

  

Date

/s/    RICHARD A. KING        

     

President, Chief Executive Officer and Director (Principal Executive Officer)

   March 17, 2014
RICHARD A. KING       

/s/    JAMES H. WELCH        

JAMES H. WELCH

     

Chief Financial Officer (Principal Financial and Accounting Officer)

   March 17, 2014

/s/    ADRIAN ADAMS        

      Chairman of the Board of Directors   March 17, 2014
ADRIAN ADAMS       

/s/    PAMELA P. PALMER, M.D., PH.D.        

      Director   March 17, 2014
PAMELA P. PALMER, M.D., PH.D.       

/s/    STEPHEN J. HOFFMAN, PH.D., M.D.        

      Director   March 17, 2014
STEPHEN J. HOFFMAN, PH.D., M.D.       

/s/    RICHARD AFABLE, M.D.        

      Director   March 17, 2014
RICHARD AFABLE, M.D.       

/s/    HOWARD B. ROSEN        

      Director   March 17, 2014
HOWARD B. ROSEN       

/s/    MARK WAN        

      Director   March 17, 2014
MARK WAN       

/s/    MARK G. EDWARDS        

      Director   March 17, 2014
MARK G. EDWARDS       

EXHIBITS

 

Exhibit

Number

   

Description

  3.1    Amended and Restated Certificate of Incorporation of the Registrant.(1)
  3.2    Amended and Restated Bylaws of the Registrant.(2)
  4.1    Reference is made to Exhibits 3.1 and 3.2.
  4.2    Specimen Common Stock Certificate of the Registrant.(3)
  4.3    Second Amended and Restated Investor’s Rights Agreement, among the Registrant and certain of its security holders, dated as of November 23, 2009.(4)
  4.4    Warrant to Purchase Stock of the Registrant, issued to Wells Fargo Bank, N.A., dated March 15, 2007.(5)
  4.5    Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P., dated as of December 16, 2013.(6)
  4.6    Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, dated as of December 16, 2013.(7)
  4.7    Form of Warrant issued to certain purchasers pursuant to the Securities Purchase Agreement dated May 29, 2012, between the Registrant and the purchasers identified therein.(8)
  5.1    Opinion of Cooley LLP.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Cooley LLP (included in Exhibit 5.1).
24.1    Power of Attorney. Reference is made to the signature page of this Form S-8.
99.1    2011 Equity Incentive Plan.(9)
99.2    Forms of Stock Option Grant Notice, Stock Option Exercise Notice and Stock Option Agreement under 2011 Equity Incentive Plan.(10)
99.3    Form of Restricted Stock Unit Award Agreement under 2011 Equity Incentive Plan.(11)

 

(1) Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35068), as filed with the Commission on February 18, 2011.
(2) Incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on January 7, 2011, as amended.
(3) Incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on January 31, 2011, as amended.
(4) Incorporated herein by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on November 12, 2010, as amended.
(5) Incorporated herein by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-170594), as filed with the Commission on November 12, 2010, as amended.
(6) Incorporated herein by reference to Exhibit 4.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March     , 2014.
(7) Incorporated herein by reference to Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March     , 2014.
(8) Incorporated herein by reference to Exhibit 4.8 to the Registrant’s Current Report on Form 8-K (File No. 001-35068), as filed with the Commission on May 30, 2012.
(9) Incorporated herein by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-172409), as filed with the Commission on February 24, 2011.
(10) Incorporated herein by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 30, 2011.
(11) Incorporated herein by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-35068), as filed with the Commission on March 30, 2011.
EX-5.1 2 d693441dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

March 17, 2014

AcelRx Pharmaceuticals, Inc.

351 Galveston Drive

Redwood City, CA 94063

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by AcelRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of a Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission covering the offering of up to an aggregate of 1,722,023 shares of the Company’s Common Stock, par value $0.001 per share, consisting of 1,722,023 shares (the “2011 EIP Shares”) pursuant to the Company’s 2011 Equity Incentive Plan (the “2011 EIP”).

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the 2011 EIP, (c) the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, and (d) such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.

As to certain factual matters, we have relied upon a certificate of officers of the Company and have not sought to independently verify such matters. Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the 2011 EIP Shares, when sold and issued in accordance with the 2011 EIP, and the Registration Statement and applicable related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement.

 

Sincerely,
Cooley LLP
By:  

/s/ Mark B. Weeks

  Mark B. Weeks

FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM

EX-23.1 3 d693441dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2011 Equity Incentive Plan of AcelRx Pharmaceuticals, Inc. of our report dated March 17, 2014, with respect to the financial statements of AcelRx Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of AcelRx Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2013 filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Redwood City, California

March 17, 2014

GRAPHIC 4 g693441logo.jpg GRAPHIC begin 644 g693441logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`/0"&`P$1``(1`0,1`?_$`*0```(!!`,!```````` M```````)"`(#!`! MD:$R(_#!T;'A\4)2,S3_V@`,`P$``A$#$0`_`/?QHB-$1HB-$1HB-$1HB-$1 MHB-$1HB-$1HB-$1HB-$1HBPWBGE)B83G(4"&,(D,0@T+03")U!`A"D+41$>P M:T<\-MQ01.D-6D@!*LY">ZEBO%EV.<=XSMN;S=?<>Y.R>-[5=D0@&J%2;AT(X0(`U$#>6!NQ1UI')+3O..JF?BP,;0&I3 M:L"YZLGD7C6*RGC]Q(JVU(KN6@ED4/1/64G&K)H/6+@A3G*KM45[@.TQ:"'0 M==&(D-J]>U9D?(&4^+3:Y\D7G<=\W&:][ MG8FG;HDW$M*&9M3M0;MA=N3&4\E$#CM+6@5UC`=(Z+=(2X]:VSF!LI;'W17@ MF3AT[B(CJV9&DT59K2!=55TWM65:4-00H-.GSIIO:MVBHNJBC4H#6O[_`//6 M0YI-%&X$+&45`I@`RHD#>`=1Z#4`Z5UOO8+'55PR>=^V$FC->OBLC^0?$/?O M7^H/C76M1KP5G<-?U5*E]V#DI<6%<36W8-DKF9W5F1S,6^O)I;O6Q%K-V[9. M9>1HE.40D'!WJ2"8]P\P1#KJAF2!CFMZ:_LKN$=I+CPI^ZV#P%X:65QYQ;;T M_)PK1[ER[H9C.7;<+Y$KI['JRK=%ZE%1"BI!*Q!#?54Y*',L8]1'2)M1N*S- MEDNU[JG]*Q$=.L',1,QS.7C7:?E/&$JV3?L%DCAL4(LFN51%0VT>E2C0=7"R MK;ZU57Q`>%.Q:.@+*Q+Q*Q5>:T.;[0QK"R%QY"DR+./-;0ZC\J+N429%6WF% M-RX1$4T^Q!4VE```-59B6BE[+#1O-!JE4P/(+G_S;F)>4XR_;V$L+1SYA9U)MX^8N.$20)(0I%P`PN'4@QBVS^.=E[$!=$6)_P"= M0!UDR/XW61'CNT_HFV1^=<;2F%T\\$N%)/&SBU`N8)XYMRJ;0"BHLU51WE(, MB+D`23)TW*#3L.I7R*FUE74&J4M#\A>?W."6EY7C)]"POAB)?.(Z+O::;%%W M<*J0F\M?UCQJ]5<+C3^\DU1,BW'H)AU4\2;?86J%?;'CL%7T)5%R9T]Q'A`\ MC;GY##;F=L*+/T8^:GXA-(TQ$F*QBA^299DN_+9RGQ-R'D*SY+ZI;ESX@N:7C'0'*H4_J(5RFLFH) M>A7;$Z8HK$'H4X5[ZT>_Q&;30A10#;.WM42/:(<"TX6D=BL5NBVR%>2SI92A M4TVR9FXJ+*JB8H(H(4!10WP3(/SU8C(CBJ%OE"LP"TG/\L^8G+[+-VX^X6IQ M5H8ULZ05C)'*4DW045>^23&9'"UTG$KXM\YB]R'@\ZB;VSG,V]G3#;Z0:1]PS$63/74A0"%COMJIF\J4:D!4U8^Z8@2LY8`0*!?)1=JD!RB3_P M+$UKXIX**:$L=0A+J]XGG%EGC/!89Q)Q@68*\F,^WQ&PUGI2$>SF0CX-!=-D MLY/%O!50,M)R4@DV0WI^(/,'J)0U6=ER,F+!J5]?]J/0^/ZAAYCS?F-N78L# MB3H"ZENW;J?@F@!;F9/_`%K&V?U&1_7C],_0_J7]N1'I!R1](`?K/VUY/T?T M'UWP>3LV>3UI772H[R]/]]J^-!D?G#%7\7F:5ZMXO\DI3WM;7FT3<=\E,6BC MR,@I*Z[=>ID`XII/7JMO3L8JYH`D33%2$.!3&$`$U`[CKFP20RMXV_=.0P=D"W\HXGL*_;9>IO8FXK9B':!R["JI+)L$$'C)RF41%-T MR=)'3.0U#%$M!`-=/'D$D5%RYXS$\]*VOYA`H%0`1K0.E1IWI\Z:G;&&=T*` M2AP2S/=H?2S/AI>Q8@RA4W%RV>RFE$/$)(M:43.N"@%`1(`K`EW_``^>N=S. M9T;`0NKRJ`/?M)NM^<*FMIQ?%+`Y+602)$K8YB7BPH@!"J2*K=(9]=Z8*@=T MI)JGW@/BW`.F-&)8626[S05%ECP\A[!P<5VGE8SMJ3XXYS;7<9N,'^F5T"^* MY+N1(X;Q;AW&G+\/,"42;FV]ZAJ8P`="KM=:MZ)",-*WH/LZ74D1=T$:7-2< M4W7VF,9.T3OH0SS<``(@W3N`ZYC#V#XZIMC(UM==.2(;N%:)YG"EE:L=Q9P: MC9J35.$4L:*<"5G0I%))9,`EE%P"H$7%^8PB4>NK\4FPAO"JYV1*6U7:^5\? M:\KQOS4RO#TQH`^.+D%Z1WM%$RR<>JK&;RFI4WU4B.S^NFJN91Q==28??>&] M/\)8W!)[+._:URF$HHJJBW9YA2AC+'`1^EJ13=T?R@[BB,FNXI\*@/RU#M+8 M37]74\D/AS@\5\_@%59KC#E3&%GV*\N:6;RPTU6;$9'F]`.M2S.I$RU_HI09*XX^Z3DJRK@LG(F:\+2]EW# M'+,YQDHU;,$UF]2*);G7TCX116D80[X`I;W&23=<$.;61.--ZR)&V)\GK_<-@RS M]84X]DZ=>>_MM4QS[$4JLRN&3E41`I5$"`80$0UPY)'PS'=]BZ.?F23>4AQF MDS3_`(C2]U#CB0TF/6]2\P1Q&D"0&+FZV\S)[.PP/8>SA(K3:HN MB^:OIU0E1,F9)I%2U>S^5^G_6T,7MY[7XGHH[6W10'"U]5V^8]Q#FQDA%:W<0\-[EM^\7:8-C34A&7)*D:.R[41<)-9"(A8 M@7.VHD4VII873Q4?6 MI5..9L$FZ/AHH&6A`\]O;WJ'VBLB9NX:G,`[!ZZK-$T+1$UCMK;!7]V)D_DEX"FTQ MU+8K<<;L+O'+9Q>$Q+>L]1,M470F51-8:#36V_( M/^CEDMP&7#FDIK\?Q=QO'\=DN,B44J./_M,;8=#Y"0.EUZ%%:Y!4$!*>76D2 M`YH-:]JZO/C)%.IVX!FW(0'LK*O M&2ZAPV`-#.IB0<&4J8:E$=M=798W'&VM'>M;XKENR'/R>]]G3P6B_;0PU?F- M>)RF.\OV+(VE*OKLN\TA;$Z0BJ[N%EDTVX"NB)U`*B[(8:=1Z!UZ:BBC>V$M M<#6JQ,YKI:@U"A^1[OF^.5EN,TX&O:0/+N;1`IGSN&-XO2LWD6X2)*27T^2!DD)S*E1:E%94Q`3,($,8= M",HD4:X?!0R18[!W7`DIP>#L5_HCB:SL8GN:8NQ6T8E%@>X+@?N7DE)K%.)E M7&]VHJJW;*KF-Y+?>9-`@`0@B`!KI8AD`+)-2J#=D$XG>0(2"TDZ=*11_P#0 M_<%CVKAK$\K&NS(9_NN[%K%Q^SB3G+.REI/FRBUS"`MU//$C!T9,K4X!7U2^ MPO4=>;]02"/;"QP\RXV'$K[A[!>C(O6?J2>;/`'*,)AE$A^W<*4OI=,6]K#A M^VX?<.\7V0\8IHY`N*,;W]DMP"8%+D18K!.");DUUU-/HO*^Z_K;)]5>H\B9A#H(/PL`-:B.C*CMVID_P#< M]&/]OQTV[/PW@7_CKKT=MIQ7S+<[P:T[RS=;J=6CI@8V\/S@7:`A2M*B-*T` MP=_GK/5P2II18Q4G`*"84PE`0#I4:B8.@]?^IMI3\*Z)3K61HBXH`=@#1%0BY?C=WU3S1I<\BS@QW"O"C>OK7JM M/?=E0P0S&0NB"9.)MR[80:3J1;H+3+YDLHD]:,";@*[?-5BB19-*HIJ>$:#3 M7LFR&1H>.*_'[\9LKW2-!N:GM.OUJN]^:3TWF_R[-U*&K7_;MIOWUZ4I6O3O MK-_BM/#%/#X+(UA91HB-$1HB-$1HB-$1HB-$1HB-$1HB-$2XO=,6Y*..)-_6 MKQ1QW=F0,OY#:_8,=]HNXID^M2"N$BJ5RW09Q+RD4W(X9PZ2B+404$Q'"Y1` M-4>:1S3EK`FI;+TWE&`S!F*)MMHPD9Z->/4IABWB$`=/HUBZ0LV(<-$1 M(#D3%5\TQ0/3KRN1.NZZ%KB@6,0Z"4 MDW*3)R`I&563*BL0Y1*'?79Q7.;$&2!P<">'6:+Q>?+R^.1SL5\9C+6BE1K0 M;M*\:_!,'H/H!\'_`&]WE[3U^!MNVGF;_P"-=6:VJO,;V^+OOM6?K*A1HB-$ =1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7_]D_ ` end